Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Equity (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Return on Equity for 13 consecutive years, with 0.17% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 49.0% year-over-year to 0.17%, compared with a TTM value of 0.17% through Dec 2025, down 49.0%, and an annual FY2025 reading of 1.06%, up 64.0% over the prior year.
  • Return on Equity was 0.17% for Q4 2025 at Heron Therapeutics, up from 0.26% in the prior quarter.
  • Across five years, Return on Equity topped out at 5.43% in Q2 2023 and bottomed at 582.18% in Q3 2022.
  • Average Return on Equity over 5 years is 45.83%, with a median of 0.22% recorded in 2025.
  • The sharpest move saw Return on Equity plummeted -58057bps in 2022, then surged 58579bps in 2023.
  • Year by year, Return on Equity stood at 2.22% in 2021, then crashed by -337bps to 9.7% in 2022, then skyrocketed by 137bps to 3.58% in 2023, then plummeted by -91bps to 0.31% in 2024, then crashed by -156bps to 0.17% in 2025.
  • Business Quant data shows Return on Equity for HRTX at 0.17% in Q4 2025, 0.26% in Q3 2025, and 0.04% in Q2 2025.